title: Predictors of influenza vaccination in the Cystic Fibrosis Foundation patient registry, 2006 through 2007.
abstract: BACKGROUND
  Influenza vaccination is recommended for all persons with cystic fibrosis (CF). Despite this recommendation, no study has been performed to determine factors associated with receipt of influenza vaccination among persons with CF.
  
  
  METHODS
  We conducted a 2-year cohort study from 2006 through 2007 using the CF Foundation (CFF) Patient Registry to assess predictors of influenza vaccination with logistical regression modeling.
  
  
  RESULTS
  In 2006, the cohort consisted of 16,435 persons with vaccination data seen at CFF care centers. Vaccination rates were high for children aged < 5 years (90.5%), children 5 to < 18 years (91.1%), and adults (87.9%). In 2006, decreased odds of vaccination were seen among adults with other or unknown insurance (0.37; 95% CI, 0.15-0.87). Among children 5 to < 18 years and adults, decreased odds of vaccination were seen among Hispanics (children, 0.74; 95% CI, 0.55-0.98; adults, 0.67; 95% CI, 0.46-0.98) and with use of oxygen therapy (children, 0.55; 95% CI, 0.38-0.78; adults, 0.68; 95% CI, 0.55-0.86), whereas four or more clinic visits annually was associated with increased odds of vaccination (children, 2.33; 95% CI, 1.92-2.84; adults, 2.05; 95% CI, 1.71-2.47). Findings associated with decreased vaccine receipt remained significant in sensitivity analyses that assumed missing vaccination data were vaccine positive.
  
  
  CONCLUSIONS
  Overall influenza vaccination rates are very high in the US CF population. Knowledge of influenza vaccination predictors among persons with CF may aid clinicians in targeting patients at greater risk for influenza infection. These data may have important implications for the evolving pandemic 2009 influenza A(H1N1).
authors.affiliation: Division of Pulmonary and Critical Care Medicine, University of Washington Medical Center, Seattle, WA 98195-6522, USA. jrortiz@u.washington.edu
authors.forename: Justin R
authors.initials: JR
authors.lastname: Ortiz
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Neuzil
authors.forename: John C
authors.initials: JC
authors.lastname: Victor
authors.forename: Moira L
authors.initials: ML
authors.lastname: Aitken
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Goss
mesh_terms: D000293:Adolescent; D000704:Analysis of Variance; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D016001:Confidence Intervals; D003550:Cystic Fibrosis / Q000175:diagnosis / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D005582:Foundations; D006801:Humans; D015994:Incidence; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D016015:Logistic Models; D008297:Male; D015999:Multivariate Analysis; D016017:Odds Ratio; D011237:Predictive Value of Tests; D012042:Registries; D018570:Risk Assessment; D014481:United States; D014611:Vaccination / Q000706:statistics & numerical data*; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines